4.6 Article

The Promise and Peril of Chemical Probe Negative Controls

期刊

ACS CHEMICAL BIOLOGY
卷 16, 期 4, 页码 579-585

出版社

AMER CHEMICAL SOC
DOI: 10.1021/acschembio.1c00036

关键词

-

资金

  1. AbbVie
  2. Bayer AG
  3. Boehringer Ingelheim
  4. Canada Foundation for Innovation
  5. Eshelman Institute for Innovation
  6. Genentech
  7. Genome Canada through Ontario Genomics Institute [OGI-196]
  8. EU/EFPIA/OICR/McGill/KTH/Diamond Innovative Medicines Initiative 2 Joint Undertaking [875510]
  9. Janssen
  10. Merck KGaA
  11. Merck Co
  12. Pfizer
  13. Takeda
  14. Wellcome [106169/ZZ14/Z]
  15. NSERC [RGPIN-201904416]

向作者/读者索取更多资源

The study compared the selectivity profiles of four chemical probes and their respective negative controls, finding that chemical modifications neutralizing the charge can result in up to 80% of known off-targets being inactive against the control. Careful selection of negative controls for chemical probes is emphasized, and it is best practice to verify that two unrelated chemical probes targeting the same protein elicit the same phenotype.
Chemical probes are selective modulators that are used in cell assays to link a phenotype to a gene and have become indispensable tools to explore gene function and discover therapeutic targets. Chemical probe off-targets are a confounding factor as the observed phenotype may be driven by inhibition of an unknown off-target instead of the targeted protein. A negative control, a close chemical analog of the chemical probe that is inactive against the intended target, is typically used to verify that the phenotype is indeed driven by the targeted protein. Here, we compare the selectivity profiles of four unrelated chemical probes and their respective negative controls. We find that controls that chemically deviate from the probe by a single heavy atom can be inactive against up to 80% of known off-targets if the chemical modification has a charge-neutralizing effect. In such cases, a loss in phenotype upon treatment with the negative control may be driven by loss of inhibition of an off-target. To expand this analysis, we inspect the crystal structures of 90 pairs of unrelated proteins, where both proteins within each pair is in complex with the same drug-like ligand. We computationally estimate that in 50% of cases, methylation of the ligand (a simple chemical modification often used to generate negative controls) at a position that will preclude binding to one protein (the intended target) will also preclude binding to the other (the off-target). These results emphasize the need to select negative controls with care and profile both chemical probes and negative controls against diverse protein arrays to verify that off-targets of probes are also hit by negative controls. When available, a best practice should be to verify that two unrelated chemical probes targeting the same protein elicit the same phenotype.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据